1 cva study sessions 2014
-
Upload
college-of-venereologists -
Category
Documents
-
view
219 -
download
4
description
Transcript of 1 cva study sessions 2014
![Page 1: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/1.jpg)
Cardiovascular Disease Risk Factors in HIV Patients
A Prospective Cohort Analysis among HIV Patients on Non Protease Inhibitor Based Antiretroviral
Therapy
A.A.I.N Jayasekara
![Page 2: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/2.jpg)
A.A.I.N Jayasekara A.V.S.N.D Ranasinhe
Neushka HerathH.A.C.W Hathurusinghe
L.N SiriwardenaD.M.M.P.K pathiraja
M.K.S.H Jayasena N.D.V N Jayasuriya
DACL Dalugama K.A.M Ariyarathne
Senior Registrars, Post Graduate Institute of Medicine, University of Colombo, Sri Lanka 2. Medical Intern, National Hospital Sri Lanka 3. Consultant
Venereologists,National STD/AIDS Control Programme, Sri Lanka
![Page 3: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/3.jpg)
Introduction In Sri Lanka Percentage of all deaths due to
cardiovascular disease (CVD) in 2008 - 29.6 %
The recent estimates for mortality from CVD for Sri Lanka was 524 deaths per 100,000 which is higher than that observed in many high-income countries
Coronary artery disease (CAD) is the leading cause of death in Sri Lanka while stroke is the third cause of death
For comparison, CAD accounts for only 17% of deaths in the US and UK
![Page 4: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/4.jpg)
Between 2005 and 2010 and beyond, significant increase in hospitalization is projected for three diseases: HD 29%, DM 36%, and HT 40%
The CAD risk factors are high and increasing: DM 7%, HT 27%, obesity 18%, high cholesterol 17%, and abdominal obesity 50%
Median body mass index (BMI) was 20 units smoking was very high at 58%
A large national study in Sri Lanka has demonstrated that living in urban areas is associated with 2-3 fold rate of physical inactivity, obesity, and diabetes
Reference : Allender S, Wickramasinghe K, Goldacre M, Matthews D, Katulanda P. Quantifying Urbanization as a Risk Factor for Noncommunicable Disease. J Urban Health. Jun 3 2011
![Page 5: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/5.jpg)
Objective
To estimate the emergence of cardiovascular disease (CVD) adverse events among HIV-infected persons who are on non PI based ARV regimen
![Page 6: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/6.jpg)
Methods
Baseline data from 120 subjects enrolled, a prospective cohort study initiated in 2012
Assessment of CVD risk factors and calculation of the Framingham score was done as a baseline
Cohort was followed up for 30 months to see any development of adverse cardiovascular outcomes
![Page 7: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/7.jpg)
Data was collected based on following variables
Age and sex ART regimen and duration CD4 counts Height/ weight and BMI Lipid profiles History of CVA History of gycemic control Treatment history … Hypertension, DM, Statins.. Alcohol and Smoking
![Page 8: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/8.jpg)
Measured CVA outcomes were 1. Coronary heart disease (CHD): Myocardial
infarction (MI), angina pectoris, heart failure(HF), and coronary death
2. Cerebrovascular disease, stroke and transient ischemic attack (TIA)
3. Peripheral arterial disease, intermittent claudication and significant limb ischemia
4. Aortic disease: Aortic atherosclerosis, thoracic aortic aneurysm, and abdominal aortic aneurysm
![Page 9: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/9.jpg)
Calculated the Framingham Score for all the patients to estimate risk of CVD in 10 years.
(updated version of Framingham General Cardiovascular Risk Score 2008)
Following parameters were assessed 1. Dyslipidemia2. Age range3. Hypertension treatment4. Smoking5. Total cholesterol
![Page 10: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/10.jpg)
![Page 11: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/11.jpg)
Framingham Risk Score for Women
Age: 20–34 years: Minus 7 points. 35–39 years: Minus 3 points. 40–44 years: 0 points. 45–49 years: 3 points. 50–54 years: 6 points. 55–59 years: 8 points. 60–64 years: 10 points. 65–69 years: 12 points. 70–74 years: 14 points. 75–79 years: 16 points
Total cholesterol, mg/dL: Age 20–39 years: Under 160: 0 points. 160-199: 4 points. 200-239: 8 points. 240-279: 11 points. 280 or higher: 13 points. • Age 40–49 years: Under 160: 0 points. 160-199: 3 points. 200-239: 6 points. 240-279: 8 points. 280 or higher: 10 points. • Age 50–59 years: Under 160: 0 points. 160-199: 2 points. 200-239: 4 points. 240-279: 5 points. 280 or higher: 7 points. • Age 60–69 years: Under 160: 0 points. 160-199: 1 point. 200-239: 2 points. 240-279: 3 points. 280 or higher: 4 points. • Age 70–79 years: Under 160: 0 points. 160-199: 1 point. 200-239: 1 point. 240-279: 2 points. 280 or higher: 2 points.
If cigarette smoker: Age 20–39 years: 9 points. • Age 40–49 years: 7 points. • Age 50–59 years: 4 points. • Age 60–69 years: 2 points. • Age 70–79 years: 1 point.
All non smokers: 0 points
HDL cholesterol, mg/dL: 60 or higher: Minus 1 point. 50-59: 0 points. 40-49: 1 point. Under 40: 2 points
Systolic blood pressure, mm Hg: Untreated: Under 120: 0 points. 120-129: 1 point. 130-139: 2 points. 140-159: 3 points. 160 or higher: 4 points. • Treated: Under 120: 0 points. 120-129: 3 points. 130-139: 4 points. 140-159: 5 points. 160 or higher: 6 points
![Page 12: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/12.jpg)
10-year risk in % for Females
Under 19 points <1020 points 1121 points 1422 points 1723 points 2224 points 27>25 points Over 30
![Page 13: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/13.jpg)
Framingham Risk Score for Men Age: 20–34 years: Minus 9 points. 35–39 years: Minus 4 points. 40–44 years: 0 points.
45–49 years: 3 points. 50–54 years: 6 points. 55–59 years: 8 points. 60–64 years: 10 points. 65–69 years: 11 points. 70–74 years: 12 points. 75–79 years: 13 points
Total cholesterol, mg/dL: Age 20–39 years: Under 160: 0 points. 160-199: 4 points. 200-239: 7 points. 240-279: 9 points. 280 or higher: 11 points. • Age 40–49 years: Under 160: 0 points. 160-199: 3 points. 200-239: 5 points. 240-279: 6 points. 280 or higher: 8 points. • Age 50–59 years: Under 160: 0 points. 160-199: 2 points. 200-239: 3 points. 240-279: 4 points. 280 or higher: 5 points. • Age 60–69 years: Under 160: 0 points. 160-199: 1 point. 200-239: 1 point. 240-279: 2 points. 280 or higher: 3 points. • Age 70–79 years: Under 160: 0 points. 160-199: 0 points. 200-239: 0 points. 240-279: 1 point. 280 or higher: 1 point.
If cigarette smoker: Age 20–39 years: 8 points. • Age 40–49 years: 5 points. • Age 50–59 years: 3 points. • Age 60–69 years: 1 point. • Age 70–79 years: 1 point.
All non smokers: 0 points
HDL cholesterol, mg/dL: 60 or higher: Minus 1 point. 50-59: 0 points. 40-49: 1 point. Under 40: 2 points
Systolic blood pressure, mm Hg: Untreated: Under 120: 0 points. 120-129: 0 points. 130-139: 1 point. 140-159: 1 point. 160 or higher: 2 points. • Treated: Under 120: 0 points. 120-129: 1 point. 130-139: 2 points. 140-159: 2 points. 160 or higher: 3 points
![Page 14: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/14.jpg)
10-year risk in % for Males
Under 11 points <10%12 points 10%13 points 12%14 points 16%15 points 20%17 points or more over 30%
![Page 15: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/15.jpg)
Estimated Risk levels
Low risk (<10% 10-year risk)
Intermediate (10–20% risk)
High risk category (≧ 20% risk)
![Page 16: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/16.jpg)
Results
The mean age of the study cohort was 46.9 years
25% of the study population was at an age where there is an appreciable risk of CVD
53.2% were males and 46.8% were females
05
101520253035404550
20-34 35-39 40-44 45-49 50-54 55-59 60-64 65-70 >70
Male Female
![Page 17: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/17.jpg)
Results cont.. All on NRTI plus NNRTI based
regimen over a mean 6.8 years (range 2-13 yrs) with SD 2.89 Yrs
79 on AZT, 29 on TDF and 1 on ABC based NRTIs
97 on EFV & 12 on NVP as NNRTI
Mean baseline CD4 count was 600 cells/mm ( median 569) and that was not statistically significant after 30 months (mean 674 cells/ql, median 635 cells/ql p=0.4)
0
10
20
30
40
50
60
2 Years 2-4 Years 4-6 Years 6-8 Years 8-10Years
10-12Years
>13Years
![Page 18: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/18.jpg)
Total cholesterol level (p= 0.32), triglycerides (p= 0.94), HDLs (p= 0.22) and LDLs (p= 0.91) were not subjected to change over a period of 30 months
The baseline BMI (mean 22.6) was not significantly different after 30 months (mean 22.4, p= 0.66)
41.8% were cigarette smokers
![Page 19: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/19.jpg)
Results…
Thirty two individuals were started on lipid lowering drugs and all of them were belongs to the above 55 age group
21 ( 19%) Diagnosed HT & on medical management
34% were physically inactive and they were regularly advised on diet and exercise
![Page 20: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/20.jpg)
Results…
Only one person developed a myocardial infarction
Two (1.8 %)persons developed diabetes
Thirteen (11.92%)developed unstable angina and currently under medical management
None were reported with CVA, peripheral arterial disease or aortic diseases
![Page 21: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/21.jpg)
Results…
FRS identified majority of individuals as low risk (<10% 10-year risk) i.e. before 81 % /after 79%
13% Vs 12% with intermediate (10–20% risk)
8% belongs to the high risk category after the intervention (≧ 20% risk)
We lost 11 patients during this follow up. All deaths were not related to CVA events
![Page 22: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/22.jpg)
Results …
The lady who developed a MI had an intermediate risk
Almost all the patients who developed UA were belongs to very low risk category at the time of enrolment
All the patients who categorized as high risk were put on statins during this follow up
None developed CV adverse events
![Page 23: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/23.jpg)
Conclusion…
Although the cohort exhibited multiple known risk factors for CVD the incidence of developing an adverse cardiovascular event is low during this follow up period
![Page 24: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/24.jpg)
Limitations..
Small sample size
Need further follow up
Need a control to compare the effects of non PI based ART regimens among HIV cohort
FS is validated for HIV patients, but there is a HIV specific prediction tool (Not validated yet)
![Page 25: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/25.jpg)
Acknowledgement
Dr. Kulasiri Budhakoraka Consultant Venereologist, Ex. HIV care coordinator
Dr. Lilani Rajapakse Consultant Venereologist HIV care coordinator, NSACP, Sri Lanka
HIV Clinic staff, NSACP, Colombo
![Page 26: 1 cva study sessions 2014](https://reader033.fdocuments.us/reader033/viewer/2022042705/568ca5b81a28ab186d8e3a4f/html5/thumbnails/26.jpg)
Thank you